First results from the double-blind placebo (PL)-controlled randomised phase III MERiDiAN trial prospectively evaluating plasma (p)VEGF-A in patients (pts) receiving first-line paclitaxel (PAC) plus /- bevacizumab (BV) for HER2-negative metastatic breast cancer (mBC)

被引：9

作者：

Miles, D. ^{[1
]}

Cameron, D. ^{[2
,3
]}

Bondarenko, I. ^{[4
]}

Lyudmila, M. ^{[5
]}

Alcedo, J. C. ^{[6
]}

Lopez, R. I. ^{[7
,8
]}

Im, S. A. ^{[9
]}

Canon, J. L. ^{[10
]}

Shparyk, Y. ^{[11
]}

Yardley, D. ^{[12
,13
]}

Masuda, N. ^{[14
]}

Ro, J. ^{[15
]}

Hubeaux, S. ^{[16
]}

Quah, C. ^{[17
]}

Bais, C. ^{[17
]}

O'Shaughnessy, J. ^{[18
,19
]}

机构：

[1] Mt Vernon Canc Ctr, Med Oncol, Northwood, Middx, England

[2] Univ Edinburgh, Edinburgh, Midlothian, Scotland

[3] NHS Lothian, Canc Serv, Med Oncol, Edinburgh, Midlothian, Scotland

[4] Dnepropetrovsk Med Acad, Oncol & Med Radiol Dept, Dnepropetrovsk, Ukraine

[5] NN Blokhin Canc Ctr, Med Oncol, Moscow, Russia

[6] Ctr Hemato Oncol Paitilla, Med Oncol, Panama City, Panama

[7] Natl Oncol Inst, Panama City, Panama

[8] Ctr Oncol Punta Pacifica, Med Oncol, Panama City, Panama

[9] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea

[10] Grand Hop Charleroi, Oncol & Haematol, Charleroi, Belgium

[11] Lviv State Oncol Reg Treatment & Diagnost Ctr, Med Oncol, Lvov, Ukraine

[12] Sarah Cannon Res Inst, Nashville, TN USA

[13] Tennessee Oncol, Med Oncol, Nashville, TN USA

[14] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka, Japan

[15] Natl Canc Ctr, Ctr Breast Canc, Goyang Si, South Korea

[16] F Hoffmann La Roche Ltd, Biostat, Pharma Dev, Basel, Switzerland

[17] Genentech Inc, Global Dev BioOncol, San Francisco, CA 94080 USA

[18] Baylor Charles A Sammons Canc Ctr, US Oncol, Dallas, TX USA

[19] Texas Oncol, Med Oncol, Dallas, TX USA

来源：

EUROPEAN JOURNAL OF CANCER | 2015年 / 51卷

关键词：

D O I：

10.1016/S0959-8049(16)30816-4

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1866

引用

页码：S287 / S288

页数：2

共 50 条

[31] First-Line Bevacizumab in Combination with Capecitabine or Paclitaxel for HER2-Negative Locally Recurrent or Metastatic Breast Cancer (LR/MBC): A Randomized Phase Ill Trial.
Beslija, S.
Brodowicz, T.
Greil, R.
Inbar, M. J.
Kahan, Z.
Kaufman, B.
Lang, I.
Steger, G. G.
Stemmer, S. M.
Zielinski, C.
Zvirbule, Z.
CANCER RESEARCH, 2011, 71
[32] Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Yardley, Denise A.
Bosserman, Linda D.
O'Shaughnessy, Joyce A.
Harwin, William N.
Morgan, Susan K.
Priego, Victor M.
Peacock, Nancy W.
Bass, J. David
Burris, Howard A., III
Hainsworth, John D.
BREAST CANCER RESEARCH AND TREATMENT, 2015, 154 (01) : 89 - 97
[33] Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park, Yeon Hee
Im, Seock-Ah
Kim, Sung-Bae
Sohn, Joo Hyuk
Lee, Keun Seok
Chae, Yee Soo
Lee, Ki Hyeong
Kim, Jee Hyun
Im, Young-Hyuck
Kim, Ji-Yeon
Kim, Tae-Yong
Lee, Kyung-Hun
Ahn, Jin-Hee
Kim, Gun Min
Park, In Hae
Lee, Soo Jung
Han, Hye Sook
Kim, Se Hyun
Jung, Kyung Hae
EUROPEAN JOURNAL OF CANCER, 2017, 86 : 385 - 393
[34] Paclitaxel, bevacizumab, and everolimus/placebo as first-line treatment for patients with metastatic HER2-negative breast cancer: a randomized placebo-controlled phase II trial of the Sarah Cannon Research Institute
Denise A. Yardley
Linda D. Bosserman
Joyce A. O’Shaughnessy
William N. Harwin
Susan K. Morgan
Victor M. Priego
Nancy W. Peacock
J. David Bass
Howard A. Burris III
John D. Hainsworth
Breast Cancer Research and Treatment, 2015, 154 : 89 - 97
[35] Bevacizumab (Bev) combined with either capecitabine (X) or weekly paclitaxel (Pac) as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): the CECOG phase III TURANDOT trial
Lang, I.
Inbar, M.
Steger, G.
Greil, R.
Zvirbule, Z.
Beslija, S.
Kahan, Z.
Taskova, V.
Kaufmann, B.
Zielinski, C. C.
EJC SUPPLEMENTS, 2009, 7 (02): : 277 - 278
[36] SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) plus bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results
Mayer, E.
Kozloff, M.
Qamar, R.
Klencke, B.
Balkissoon, J.
Parmar, H.
Samant, M.
Burstein, H. J.
CANCER RESEARCH, 2009, 69 (02) : 239S - 240S
[37] First-line bevacizumab (B) plus paclitaxel (P) in HER2-negative (HER2-ve) metastatic breast cancer (mBC): Efficacy and safety in an Italian multicenter retrospective study
Andreis, D.
Scandurra, G.
Santini, D.
Gucciardino, C.
La Verde, N. M.
Girelli, S.
Alabiso, I.
Saetta, A.
Atzori, F.
Collova, E.
Ferzi, A.
Gori, S.
Lipari, H.
Saggia, C.
Marcon, I.
Generali, D. G.
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
[38] QUALITY OF LIFE (QOL) AMONG PATIENTS (PTS) WITH LOCALLY RECURRENT (LR) OR METASTATIC BREAST CANCER (MBC): RESULTS FROM THE PHASE III AVADO STUDY OF FIRST-LINE BEVACIZUMAB (BV) PLUS DOCETAXEL (D) VERSUS D PLUS PLACEBO (PL)
Greil, R.
Im, Y. H.
Pienkowski, T.
Wardley, A.
Awada, A.
Ciruelos, E.
Freitas-Junior, R.
Fumoleau, P.
Sriuranpong, V.
Miles, D. W.
ANNALS OF ONCOLOGY, 2008, 19 : 67 - 67
[39] Sorafenib (SOR) plus docetaxel (DOC) as first-line therapy in patients with HER2-negative metastatic breast cancer (MBC): A randomized, placebo-controlled phase II trial.
Marme, Frederik
Gerber, Bernd
Schmidt, Marcus
Moebus, Volker Jochen
Foerster, Frank Gerhard
Grischke, Eva-Maria
Beckmann, Matthias W.
Strumberg, Dirk
Solomayer, Erich
Klare, Peter
Windemuth-Kieselbach, Christiane
Schneeweiss, Andreas
JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[40] Results of a phase III, randomized, double-blind, placebo-controlled trial of pegfilgrastim (PEG) in patients (pts) receiving first-line FOLFOX or FOLFIRI and bevacizumab (B) for colorectal cancer (CRC)
Pinter, Tamas
Abella, Steve
Cesas, Alvydas
Croitoru, Adina
Decaestecker, Jochen
Gibbs, Peter
Hotko, Yevhen
Jassem, Jacek
Kurteva, Galina Petrova
Novotny, Jan
O'Reilly, Seamus
Salek, Tomas
Mo, May F.
Choi, L. Mi Rim
Blanke, Charles Davic
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)

← 1 2 3 4 5 →